ERβ-Mediated Alteration of circATP2B1 and miR-204-3p Signaling Promotes Invasion of Clear Cell Renal Cell Carcinoma

Han, Zhenwei; Zhang, Yong; Sun, Yin; Chen, Jiaqi; Chang, Chawnshang; Wang, Xiaolu; Yeh, Shuyuan

doi:10.1158/0008-5472.can-17-1575

Cited by 71 publications

(81 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…mRNAs were subjected to real-time qPCR using the Platinum Sybr Green qPCR Super Mix Uracil-DNA Glycosylase (UDG) Kit (Thermo Fisher Scientific) and the ABI 7500 Fast system (Thermo Fisher Scientific) with primers of RBM5 forward, 59-ACAGTCCAGAGA-GAGAGCGT-39; RBM5 reverse, 59-ACTTGTCTGCTCCACAT-CGG-39; glyceraldehyde 3-phosphate dehydrogenase (GAPDH) forward, 59-CACCATCTTCCAGGAGCGAG-39; GAPDH reverse, 59-GACTCCACGACGTACTCAGC-39. Relative transcript expression levels were normalized to GAPDH and calculated using the 2 2DDCt formula as previously described by Han et al (29).…”

Section: Rna Isolation and Real-time Pcrmentioning

confidence: 99%

“…RBM5 expression was analyzed from in bladder cancer patient datasets of GSE13507 as previously described (36). Ensembl (https://useast.ensembl.org/ index.html) and Promo 3.0 (http://jaspar.binf.ku.dk/cgi-bin/ jaspar_db.pl)) were used to search the potential TCF/LEF element on the promoter region of miR-432 as previously described (37).…”

Section: Target Prediction and Bioinformatics Analysismentioning

confidence: 99%

See 1 more Smart Citation

Down‐regulated RBM5 inhibits bladder cancer cell apoptosis by initiating an miR‐432‐5p/β‐catenin feedback loop

et al. 2019

View full text Add to dashboard Cite

RNA‐binding motif protein 5 (RBM5) acts as a tumor suppressor in various human cancers and presents with several important characteristics, such as the potentiation of apoptosis, inhibition of the cell cycle, and alternative splicing of Fas and caspase‐2 precursor mRNA. However, its role in bladder urothelial carcinoma (BUC) remains unknown. In this study, we found that RBM5 expression was significantly down‐regulated in BUC tissues when compared with the adjacent nontumor tissues. The down‐regulation of RBM5 activates ²‐catenin, which binds to the T‐cell factor/lymphocyte enhancer factor element of the miR‐432‐5p promoter and elevates the expression of miR‐432‐5p in bladder cancer cells. The up‐regulated miR‐432‐5p directly targets 3′‐UTR and depresses RBM5 expression. Thus, RBM5–miR‐432‐5p–²‐catenin forms a feedback loop in regulating bladder cancer cell apoptosis. Our findings provide evidence that the regulatory feedback loop among RBM5, miR‐432‐5p, and Wnt–²‐catenin is responsible for the progress of bladder cancer cells.—Zhang, Y.‐P., Liu, K.‐L., Wang, Y.‐X., Yang, Z., Han, Z.‐W., Lu, B.‐S., Qi, J.‐C, Yin, Y.‐W., Teng, Z.‐H., Chang, X.‐L., Li, J.‐D., Xin, H., Li, W. Down‐regulated RBM5 inhibits bladder cancer cell apoptosis by initiating an miR‐432‐5p/²‐catenin feedback loop. FASEB J. 33, 10973–10985 (2019). http://www.fasebj.org

show abstract

Section: Rna Isolation and Real-time Pcrmentioning

confidence: 99%

Section: Target Prediction and Bioinformatics Analysismentioning

confidence: 99%

Down‐regulated RBM5 inhibits bladder cancer cell apoptosis by initiating an miR‐432‐5p/β‐catenin feedback loop

et al. 2019

View full text Add to dashboard Cite

show abstract

“…CircRNA ZNF609 acts as miRNA sponge of miRNA-138-5p and modulate the expression of forkhead box P4 (FOXP4), ultimately influencing renal cancer cell proliferation. Another circular RNA (circATP2B1) also influences renal cancer cell proliferation via miR-204-3p, and increases the expression of fibronectin 1 (FN1) [51]. Wang et al identified a new circular RNA (circHIAT1) that was downregulated in ccRCC tissues [25].…”

Section: Circular Rnas In Renal Cancermentioning

confidence: 99%

“…Another class of circRNA (circATP2B1) also influenced the progression of ccRCC. Mechanistically, circATP2B1 acts as miRNA sponge of miR-204-3p and influence the expression of estrogen receptor beta (ERβ), together they influence RCC progression, suggesting circRNA ATP2B1 as prognostic biomarker for renal disease [51]. The Fibroblast growth factor receptor-like 1 expression of circPCNXL2 was significantly increased in RCC patients, indeed the higher expression corresponds to poor survival of ccRCC patients [50].…”

Section: Circular Rnas As Biomarker In Renal Cancermentioning

confidence: 99%

Noncoding RNAs and Its Implication as Biomarkers in Renal Cell Carcinoma: A Systematic Analysis

Verma¹,

Gupta²

2019

ann urol oncol

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is one of the most devastating disease with higher mortality rates. It comprises several subtypes exhibiting distinct histological features and clinical staging. Despite recent advancement in understanding the biology of RCC success in treatment rates remains dismal. This may be partly due to lack of specific biomarkers for early detection/prognosis and poor clinical outcome. Noncoding protein transcripts in the genome play important role in the initiation, evolution and progression of cancer. With the advancement in genomic analysis techniques, especially next-generation sequencing, a large number of new transcripts have been discovered, leading to better understanding of coding and noncoding RNAs. In the present review, we summarize recent advancement on renal cancer associated noncoding RNAs which includes long noncoding RNAs, microRNAs, and circular RNAs for their involvement in RCC along with their clinical implication as prognostic and diagnosis biomarkers.

show abstract

“…Furthermore, in vivo animal results indicated that supplementation of the synthetic estrogen, diethylstilbestrol, could induce RCC development (Wolf et al, 1998). Our recent reports suggested that ERb could modulate the functions of circular RNA-ATP2B1, and long non-coding RNA-HOTAIR to promote RCC progression (Ding et al, 2018;Han et al, 2018). However, how ER directly regulates RCC progression and the underlying mechanisms remain an under-investigated area that requires further investigation.…”

Section: Introductionmentioning

confidence: 99%

Targeting newly identified ERβ/TGF‐β1/SMAD3 signals with the FDA‐approved anti‐estrogen Faslodex or an ERβ selective antagonist in renal cell carcinoma

Song

Chen

et al. 2018

Molecular Oncology

Self Cite

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) has the third highest mortality rate among urological tumors, and 20–30% of RCC patients present with metastatic RCC at the time of diagnosis. Although recent studies have indicated that estrogen receptor β (ERβ) could play promoting roles in RCC progression, the detailed mechanisms remain to be clarified. In the present study, we found that expression of ERβ, but not ERα, increases with tumor stage and grade, and also observed that modification of ERβ signals using estrogens/anti‐estrogens, shRNA knockdown of ERβ and overexpression of ERβ using ectopic cDNA affects RCC cell proliferation, migration and invasion. Mechanism analysis revealed that ERβ can promote RCC cell invasion via an increase in transforming growth factor β1 (TGF‐β1)/SMAD3 signals, and interrupting TGF‐β1/SMAD3 signals with a TGFβR1 inhibitor can reverse/block ERβ‐increased RCC cell migration. Importantly, preclinical analyses using in vivo mouse models of RCC revealed that targeting of this newly identified ERβ/TGF‐β1/SMAD3 pathway with either the FDA‐approved anti‐estrogen ICI182,780 (Faslodex) or a selective ERβ antagonist 4‐[2‐phenyl‐5,7 bis(trifluoromethyl)pyrazolo[1,5‐a]pyrimidin‐3‐yl]phenol can significantly reduce RCC tumor growth and invasion, which may be suitable as the basis for novel therapies to more effectively suppress metastatic RCC.

show abstract

ERβ-Mediated Alteration of circATP2B1 and miR-204-3p Signaling Promotes Invasion of Clear Cell Renal Cell Carcinoma

Cited by 71 publications

References 48 publications

Down‐regulated RBM5 inhibits bladder cancer cell apoptosis by initiating an miR‐432‐5p/β‐catenin feedback loop

Down‐regulated RBM5 inhibits bladder cancer cell apoptosis by initiating an miR‐432‐5p/β‐catenin feedback loop

Noncoding RNAs and Its Implication as Biomarkers in Renal Cell Carcinoma: A Systematic Analysis

Targeting newly identified ERβ/TGF‐β1/SMAD3 signals with the FDA‐approved anti‐estrogen Faslodex or an ERβ selective antagonist in renal cell carcinoma

Contact Info

Product

Resources

About